Product Description
Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Brilinta cases. Here at Leading Justice, we can customize your firm’s Brilinta advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Brilinta advertising, plus a fee for each case we sign, and any Brilinta data we generate for your firm belongs to you. We also cross-qualify all of our contacts, meaning any data we generate that doesn’t qualify for the target campaign is reviewed to determine whether it is eligible for another type of claim. By using innovative approaches to target contacts specifically related to Brilinta use and side effects like internal bleeding, heart attack and stroke, Leading Justice will increase your firm’s Brilinta caseload. If you are interested in helping victims of alleged Brilinta side effects, our broad consumer reach and direct advertising strategies at Leading Justice give you the competitive edge you need, and the confidence to allocate your full budget, so you can rest easy knowing your money is being spent in the best way possible.
Each and every law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. While our experience working with plaintiff law firms helps us recognize a great case when we see one, will will custom-tailor our Brilinta case intake specifications to the exact criteria you are seeking. So, if your firm has specific Brilinta qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By getting rid of the middle man, Leading Justice offers clients the opportunity for internal cash buys of Brilinta data with zero chance of fraud.
Brilinta Side Effect Litigation
Anticoagulant medications like Brilinta (ticagrelor) are designed to reduce the risk of blood clots, heart attack and stroke in patients who have undergone certain heart surgeries, such as angioplasty, coronary artery bypass graft, or stent placement. Brilinta is categorized as an antiplatelet drug, and the prescription medication works by preventing platelets from sticking together and forming harmful clots, which can travel to the heart and lungs and cause complications like heart attack, stroke or pulmonary embolism. Unfortunately, patients who take Brilinta may also face a higher risk of bleeding complications, and because the medication does not have an approved reversal agent to counteract its blood-thinning effects, Brilinta may cause uncontrollable bleeding problems that can be fatal in some cases.
Concerns about bleeding complications and other serious injuries potentially associated with Brilinta use date back to 2013, just two years after Brilinta was originally approved, when a report published in the International Journal of Cardiology questioned the results of the PLATO clinical trial, which was sponsored by AstraZeneca and was the basis for the FDA’s approval of Brilinta. In the years since, additional studies and articles have suggested that AstraZeneca may have deliberately manipulated the clinical trial results to make Brilinta appear safer than it actually is. In light of these claims, it is likely that AstraZeneca will face dozens of claims brought on behalf of former Brilinta users who took the blood thinner without full knowledge of the potential risks it posed for their health.
